Entrada Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TRDA | ENTA | RLMD | VIVOBIOT.BO | CADL | NBP | |
|---|---|---|---|---|---|---|
| Market cap | 197.02M | 310.19M | 444.81M | 328.87M | 692.49M | 117.16M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.6 | -4.5 | -10.2 | — | -14.5 | -0.8 |
| Price/book | 0.8 | 3.1 | 2.2 | 0.3 | 5.5 | 0.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −31.99% | −5.04% | +70.12% | −58.81% | +73.28% | −76.29% |
| Today | +7.20% | +2.70% | −2.34% | +6.77% | +2.61% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TRDA news ›Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
The Manila Times Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer A seasoned global people leader and organizational strategist, Ms. Aspesi will help scale Entrada’s people and organization for its next phase of gr
Entrada Therapeutics Reports Phase 1/2 Data for ENTR-601-45 in DMD Exon 45 Skipping
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Entrada Therapeutics Reports Phase 1/2 Data for ENTR-601-45 in DMD…
Entrada Therapeutics first cohort meets safety objectives
Entrada Therapeutics (TRDA) is a clinical-stage biopharmaceutical company developing EEV-based RNA and protein therapies for Duchenne, ocular disease and DM1. Entrada Therapeutics first cohort meets safety objectives All eight Cohort 1…
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
October 14, 2026 07:00 ET | Source: Entrada Therapeutics, Inc. Entrada Therapeutics, Inc. -- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were…
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Cohort 2 enrollment is complete, with its data expected in Q1 2027 following the Cohort 1 open-label update. -- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2…
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity
Entrada Therapeutics (ENTR) Buy call: $8.50 fair value (~52% upside). Valuation is anchored by risk-adjusted pipeline estimates. See more details here. - Entrada Therapeutics is rated Buy with a $8.50 fair value, offering ~52% upside from…
Comparing Black Diamond Therapeutics (NASDAQ:BDTX) & Entrada Therapeutics (NASDAQ:TRDA)
Posted by Michael Walen on Oct 11th, 2026 Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) and Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net1
- manilatimes.net1
- seekingalpha.com1
- stocktitan.net1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.